Complete financial analysis of Saniona AB (publ) (SANION.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Saniona AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Aether Catalyst Solutions, Inc. (ATHHF) Income Statement Analysis – Financial Results
- Kontrol Technologies Corp. (KNR.NE) Income Statement Analysis – Financial Results
- Tri City Bankshares Corporation (TRCY) Income Statement Analysis – Financial Results
- PTT Exploration and Production Public Company Limited (PTXLF) Income Statement Analysis – Financial Results
- Sacheta Metals Limited (SACHEMT.BO) Income Statement Analysis – Financial Results
Saniona AB (publ) (SANION.ST)
About Saniona AB (publ)
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.84M | 15.28M | 10.48M | 8.20M | 2.66M | 54.88M | 20.69M | 74.92M | 13.63M | 21.72M | 13.64M | 7.77M |
| Cost of Revenue | 5.06M | 4.48M | 4.63M | 3.25M | 3.52M | 4.09M | 3.26M | 1.48M | 2.05M | 1.73M | 676.02K | 1.06M |
| Gross Profit | 11.78M | 10.81M | 5.85M | 4.95M | -859.00K | 50.80M | 17.43M | 73.45M | 11.58M | 19.99M | 12.96M | 6.71M |
| Gross Profit Ratio | 69.96% | 70.72% | 55.81% | 60.33% | -32.32% | 92.55% | 84.23% | 98.03% | 84.96% | 92.04% | 95.04% | 86.41% |
| Research & Development | 0.00 | 96.40M | 155.70M | 0.00 | 0.00 | 0.00 | 26.90M | 29.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 239.27M | 97.11M | 74.98M | 80.15M | 51.39M | 51.10M | 23.93M | 15.02M | 5.11M | 5.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 1.86M | 239.27M | 97.11M | 74.98M | 80.15M | 51.39M | 51.10M | 23.93M | 15.02M | 5.11M | 5.17M |
| Other Expenses | 92.85M | 236.53M | 178.15M | 67.21M | 28.06M | 24.85M | 23.23M | 18.19M | 15.73M | 13.23M | 9.55M | 3.73M |
| Operating Expenses | 92.85M | 236.53M | 417.42M | 164.32M | 103.05M | 105.00M | 74.62M | 69.29M | 39.66M | 28.25M | 14.66M | 8.89M |
| Cost & Expenses | 97.91M | 241.00M | 422.05M | 167.57M | 106.56M | 109.09M | 77.88M | 70.76M | 41.71M | 29.98M | 15.34M | 9.95M |
| Interest Income | 2.24M | 593.00K | 247.00K | 312.00K | 674.00K | 0.00 | 0.00 | 9.00K | 0.00 | 0.00 | 1.00K | 0.00 |
| Interest Expense | 24.93M | 14.71M | 10.85M | 11.35M | 221.00K | 159.00K | 376.00K | 234.00K | 46.00K | 10.00K | 22.90K | 0.00 |
| Depreciation & Amortization | 9.65M | 7.82M | 8.67M | 4.80M | 2.20M | 632.00K | 561.00K | 384.00K | 763.00K | 760.00K | 449.00K | 2.18M |
| EBITDA | -82.01M | -196.00M | -398.86M | -64.64M | -68.71M | -53.68M | -55.71M | 4.54M | -28.50M | -6.98M | -1.22M | -2.18M |
| EBITDA Ratio | -486.97% | -1,424.98% | -3,848.59% | -1,976.14% | -3,050.34% | -86.55% | -267.44% | 7.38% | -208.72% | -32.09% | -9.09% | -28.12% |
| Operating Income | -81.07M | -225.72M | -411.57M | -159.38M | -103.91M | -54.21M | -57.19M | 4.16M | -28.08M | -8.26M | -1.70M | -2.18M |
| Operating Income Ratio | -481.38% | -1,476.93% | -3,927.94% | -1,944.07% | -3,909.18% | -98.76% | -276.39% | 5.55% | -205.98% | -38.02% | -12.46% | -28.12% |
| Total Other Income/Expenses | -23.22M | 7.19M | -6.81M | 78.16M | 17.16M | 5.91M | 914.00K | 757.00K | -1.18M | 519.00K | -13.00K | -13.85K |
| Income Before Tax | -104.28M | -251.97M | -418.38M | -81.22M | -83.50M | -48.29M | -56.28M | 4.91M | -29.26M | -7.74M | -1.71M | -2.20M |
| Income Before Tax Ratio | -619.24% | -1,648.67% | -3,992.94% | -990.68% | -3,141.50% | -87.99% | -271.97% | 6.56% | -214.66% | -35.63% | -12.55% | -28.30% |
| Income Tax Expense | -8.47M | -6.61M | -7.48M | -7.79M | -7.71M | -7.23M | -7.09M | 2.70M | -6.31M | -1.83M | -423.04K | -543.42K |
| Net Income | -95.81M | -245.36M | -410.90M | -73.43M | -75.79M | -41.06M | -49.19M | 2.22M | -22.95M | -5.91M | -1.29M | -1.65M |
| Net Income Ratio | -568.94% | -1,605.42% | -3,921.53% | -895.71% | -2,851.32% | -74.81% | -237.72% | 2.96% | -168.36% | -27.20% | -9.45% | -21.30% |
| EPS | -1.29 | -3.33 | -5.57 | -1.52 | -2.49 | -1.84 | -2.23 | 0.11 | -1.29 | -0.45 | -0.09 | -0.12 |
| EPS Diluted | -1.29 | -3.33 | -5.57 | -1.52 | -2.49 | -1.84 | -2.23 | 0.11 | -1.26 | -0.43 | -0.09 | -0.12 |
| Weighted Avg Shares Out | 74.54M | 73.73M | 73.73M | 48.45M | 30.40M | 22.29M | 22.02M | 20.84M | 17.78M | 13.13M | 14.27M | 14.27M |
| Weighted Avg Shares Out (Dil) | 74.54M | 73.73M | 73.73M | 48.45M | 30.40M | 22.31M | 22.06M | 21.43M | 18.28M | 13.60M | 14.27M | 14.27M |
Source: https://incomestatements.info
Category: Stock Reports